Million Dollar Gotham Prize Announced

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 6
Volume 16
Issue 6

A group of leading scientists and hedge fund managers have announced the annual $1 million Gotham Prize for Cancer Research, which is being launched to accelerate progress in the prevention, diagnosis, and treatment of cancer by fostering collaboration among top researchers in the field.

NEW YORK—A group of leading scientists and hedge fund managers have announced the annual $1 million Gotham Prize for Cancer Research, which is being launched to accelerate progress in the prevention, diagnosis, and treatment of cancer by fostering collaboration among top researchers in the field.

The prize is open to prequalified individuals who share their ideas and concepts by posting a short thesis and/or proposal and answering questions at www.gothamprize.org, the Gotham Prize website. Each year, the member who submits the best idea in the area of cancer research as judged by an expert panel will receive $1 million for personal use. The annual $250,000 Ira Sohn Conference Foundation Prize in Pediatric Oncology will be awarded for the best idea in pediatric oncology. The 2007 winners will be revealed in February 2008.

The Gotham Prize website will serve as an ongoing forum for cancer researchers to test and exchange ideas. The website will also provide a mechanism to connect researchers with other potential sources of funding. The Gotham Prize was founded by Gary Curhan, MD, ScD, of Harvard Medical School, and investment managers from Gotham Capital, a private investment firm founded by Joel Greenblatt, MBA.

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content